A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.

Also called NCT03736785

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 399 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03736785
Other papers using this trial's data
  • Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study The lancet. Diabetes & endocrinology, 2023-03 DOI, PubMed 36758572

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03736785. Randomized; no masking; primary purpose treatment. Start 2018-11-15 (actual); primary completion 2020-02-18 (actual). Results posted on 2021-03-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY3209590
Intervention (Drug)
Insulin Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03736785
Content hash
7f5170bed23de87e52a2e0ade206bbd8de4ae3a8de887479a0058a5f22d4a80a